United States · 
Who invested in Zerigo Health?
Zerigo Health's investors include General Catalyst and SV Health Investors.
United States · Series B startup
Who invested in Zerigo Health
Funding summaryUpdated 26 Oct 2026
$43Mraised across 1 round since 2021, from 1 source
- Latest round
- Series B, $43MOct 2021
- Investors
- 2
The rounds
- Oct 2021Series B$43M
Source recordedSEC filing: $43M sold, first sale Oct 2021
Founders and team
From Zerigo Health's own website and the SEC filings it signed: 8 on the team.
- John SchellhornPresident and Chief Executive Officeri
- Carly HeimanVice President, Product
- Lisa RomettyPresident and CEO
- Dr. Christine GilroyChief Medical Officer
- Ehud GelblumChief Financial Officer
- Steve VioletteChief Operating Officer
- Tim Raducha-GraceChief Platform Officer
- Edward FulhamSecretaryi
On the board, as filediBruce RobertsonPaul LaVioletteRobert Garber
Everyone who backed them
SV Health InvestorsVC firm1round
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
These 4 firms list Zerigo Health as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.
Bluestem CapitalPrivate equityPer its own site
Quick answers about Zerigo Health
How much has Zerigo Health raised?
Zerigo Health has raised $43M across 1 round since 2021.
When did Zerigo Health last raise?
Zerigo Health's most recent round was a Series B of $43M in Oct 2021.
What was Zerigo Health's biggest round?
Its most recent round, $43M in Oct 2021, is also its largest on record.
Who backed Zerigo Health first?
Zerigo Health's first round on record, in Oct 2021, was backed by General Catalyst and SV Health Investors.
What stage is Zerigo Health at?
Zerigo Health's latest named round is a Series B, in Oct 2021.
Where is Zerigo Health based?
Zerigo Health is based in the United States.
Companies like Zerigo Health
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.